Huntsman Corporation Stock 12‑Month Price Target Raised to $11.19, Implies 17% Upside

Huntsman Corporation's average stock price target increased from $11.12 to $11.19 by 16 analysts, implying 17% upside from Nov. 3 close. 19 analysts maintain 'Hold' rating, with 4 'Buy' and 2 'Sell' recommendations.

Original reporting
Published Nov 4, 2026, 4:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 4:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Huntsman Corporation Stock 12‑Month Price Target Raised to $11.19, Implies 17% Upside — source image
Decision brief

The 30-second read

$HUNBullishLow
01

Why it matters

A modest target increase may nudge the stock higher but lacks a catalyst for a sizable move.

02

Market read

Small‑cap chemical stock with a slight upward bias from analyst revisions.

03

What to watch

No new earnings or contract news; the change reflects analyst opinion only.

Relevance 5/10Novelty 5/10Timing: today

Background

The article aggregates recent analyst price target revisions for Huntsman Corp.

Company-level read

Ticker impact

$HUNBullishMedium confidence
Context

Analysts raised the average price target for Huntsman Corp to $11.19, implying ~17% upside.

Expected impact

likely upward pressure as investors price in the higher target.

Evidence & confidence

Target increase is small and reflects consensus hold rating; impact limited to short‑term re‑rating.

Market effects

Minor positive signal for specialty chemicals sector.

Limited to US investors tracking Huntsman.

Low

Counterpoint

Target raise may already be priced in; upside limited.

Key entities

  • Huntsman Corporation

    Specialty chemicals producer.

Related articles

$HUNMed

KeyBanc raises Huntsman stock price target on merger synergies

KeyBanc raised its price target for Huntsman (NYSE:HUN) to $13, citing merger synergies with OLN and better-than-expected Q3 results. The stock trades at $9.45, with a Fair Value of $13.16. Huntsman reported mixed Q3 earnings, missing EPS estimates but exceeding revenue forecasts. Jefferies initiated coverage with a Buy rating and $12 target. The company faces rising input costs but aims for $100M EBITDA improvement in 2026.

$HUNMed

Huntsman Q3 Earnings Call Highlights

Huntsman (HUN) reported Q3 earnings, noting seasonal slowing and higher raw-material costs in North American MDI markets. The company expects 2027 industry MDI growth to be flat to 2% and sees growth opportunities in advanced materials and automotive applications. Huntsman generated $82M in free cash flow in Q3 and anticipates substantial cash inflow in Q4. Europe remains challenging due to high energy costs, while China's market shows stability.

$HUNMed

Huntsman Corp (HUN) (Q3 2026) Earnings Call Highlights: $100 Million EBITDA Boost

Huntsman Corp (HUN) reported a $100M EBITDA boost in Q3 2026, with CEO Peter Huntsman expressing confidence in meeting $300M synergy targets from the Olin merger. He discussed market positioning, cost management, and growth expectations, including GDP-plus growth in Advanced Materials through 2027. The company expects to cover its dividend and capex with operating cash flow, despite minimal cash flow in the first nine months.

$HUNMedAI 8/10

Huntsman: Q3 Earnings Snapshot

Huntsman Corp. (HUN) reported a Q3 loss of $18M, or 10 cents per share, missing analyst expectations of 7 cents per share. Adjusted earnings were 4 cents per share. Revenue was $1.72B, exceeding forecasts of $1.6B.